Comparative Pharmacology
Head-to-head clinical analysis: OMEPRAZOLE MAGNESIUM versus ZEGERID OTC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OMEPRAZOLE MAGNESIUM versus ZEGERID OTC.
OMEPRAZOLE MAGNESIUM vs ZEGERID OTC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Omeprazole magnesium is a proton pump inhibitor (PPI) that irreversibly inhibits the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, suppressing gastric acid secretion.
Omeprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by irreversibly binding to the H+/K+-ATPase enzyme (the proton pump) in the gastric parietal cells.
20 mg orally once daily for 4-8 weeks; for erosive esophagitis 20-40 mg orally once daily for 4-8 weeks; maintenance: 10-20 mg orally once daily; for Helicobacter pylori eradication: 20 mg orally twice daily for 10-14 days in combination with antibiotics.
20 mg orally once daily before a meal for 14 days for frequent heartburn; 20 mg orally once daily for up to 8 weeks for erosive esophagitis healing; 20 mg orally once daily for maintenance of healed erosive esophagitis (up to 12 months).
None Documented
None Documented
Terminal elimination half-life: 0.5-1 hour (fast metabolizers); 2-3 hours (slow metabolizers); clinical context: prolonged in hepatic impairment, no significant accumulation with once-daily dosing due to irreversible inhibition of H+/K+-ATPase.
Terminal half-life approximately 1.5-2 hours (0.5-1 hour in children); due to short half-life, acid suppression duration is prolonged via irreversible proton pump inhibition
Renal: 77% as metabolites; biliary/fecal: 16.7% as metabolites; active drug not excreted unchanged.
Renal (80% as metabolites) and fecal (20%)
Category A/B
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor